Washington, May 6, 2017: Researchers, including one of the Indian-origin, have identified a marker of damage to cells in the eye that potentially could be used to monitor progression of glaucoma and the effectiveness of treatment.
“There hasn’t been a reliable way to predict which patients with glaucoma have a high risk of rapid vision loss,” said principal investigator Rajendra Apte from Washington University School of Medicine in St. Louis.
“But we’ve identified a biomarker that seems to correlate with disease severity in patients, and what that marker is measuring is stress to the cells rather than cell death,” Apte said.
“Other glaucoma tests are measuring cell death, which is not reversible, but if we can identify when cells are under stress, then there’s the potential to save those cells to preserve vision,” Apte said.
Please Follow NewswGram on Facebook To Get Latest Updates!
Glaucoma is the second-leading cause of blindness in the world, affecting more than 60 million people.
The disease often begins silently, with peripheral vision loss that occurs so gradually that it can go unnoticed. Over time, central vision becomes affected, which can mean substantial damage already has occurred before any aggressive therapy begins.
Finding a marker of cell damage in the eye would be a much more reliable way to track the progression of glaucoma, Norimitsu Ban, an ophthalmologist and a postdoctoral research associate in Apte’s laboratory, said.
“We were lucky to be able to identify a gene and are very excited that the same gene seems to be a marker of stress to ganglion cells in the retinas of mice, rats and humans,” Ban, who is first author of the paper published online in the journal JCI Insight, said.
Studying mouse models of glaucoma, Ban, Apte and their colleagues identified a molecule in the eye called growth differentiation factor 15 (GDF15), noting that the levels of the molecule increased as the animals aged and developed optic nerve damage.
When they repeated the experiments in rats, they replicated their results. Further, in patients undergoing eye surgery to treat glaucoma, cataracts and other issues, the researchers found that those with glaucoma also had elevated GDF15 in the fluid of their eyes.
“That was exciting because comparing the fluid from patients without glaucoma to those with glaucoma, the GDF15 biomarker was significantly elevated in the glaucoma patients,” Apte said.
“We also found that higher levels of the molecule were associated with worse functional outcomes, so this biomarker seems to correlate with disease severity,” Apte said. (IANS)